Clinical trial
An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
NCT00044564 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
- Lead sponsor
- Bayer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2001
- Completion date
- January 31, 2003
- Enrollment
- 54 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.